Especifique uma ação ou criptomoeda na barra de pesquisa para obter um resumo
Defence Therapeutics Inc
DTCDefence Therapeutics Inc. develops a biological drug enhancer platform that improves the efficacy and safety of a multitude of a multitude of biological/biosimilar based pharmaceuticals used in the treatment of cancer and infectious diseases. The company focuses on the research, development, and advancement of products using its Accum technology, including antibody drug conjugates targeting various cancers; anti-cancer AccuTOX program, which has completed preclinical studies for solid T-cell lymphoma, breast cancer, and melanoma; ARM-X vaccine program, a mesenchymal stem cell-based vaccine targeting cancer; and mRNA vaccination program. It also offers Accuvac for dendritic cell cancer vaccines; a protein-based vaccine formulation against COVID and infectious diseases; and cervical cancer vaccine. The company was formerly known as Accum Therapeutics Inc. and changed its name to Defence Therapeutics Inc. in March 2020. The company was incorporated in 2017 and is headquartered in Vancouver, Canada. Address: 1680 ? 200 Burrard Street, Vancouver, BC, Canada, V6C 3L6
Analytics
Preço Alvo de Wall Street
15.33 CADRácio P/E
–Rendimento de dividendos
–Ano atual
Ano passado
Trimestre Atual
Ultimo quarto
Ano atual
Ano passado
Trimestre Atual
Ultimo quarto
Figuras chave DTC
Análise de Dividendos DTC
Crescimento de dividendos em 5 anos
–Crescimento contínuo
–Taxa de pagamento em média de 5 anos
–Histórico de Dividendos DTC
Avaliação de ações DTC
Relatório DTC
Acompanhe as principais métricas de cada ação em um só lugar, sem complicações
Inscreva-se no premiumResultados | 2019 | Dinâmica |